#United States #Cambridge #gene therapy #biotechnology #STRM.BIO

STRM.BIO Secures $8 Million in Financing for Gene Therapy Advancements

Cambridge, MA – STRM.BIO, an innovative biotechnology firm specializing in non-viral delivery technologies for in vivo cell engineering, recently announced the successful acquisition of $8 million in Series Seed 2 funding. This crucial financial boost was led by Recordati, complemented by ongoing support from notable investors such as Boehringer Ingelheim Ventures and Delos Capital, along with new support from Blue Bay Capital Fund. The Series Seed 2 funding is still open, with plans to close it by the first quarter of 2026.

This funding comes on the heels of a recently awarded $8.4 million contract from ARPA-H, bringing STRM.BIO’s total funding to an impressive $16.4 million in a short period. The company is focused on the development of its megakaryocyte-derived vesicle (MV) gene delivery platform, which aims to address critical needs in treating rare hematological diseases and advancing in vivo CAR-T therapies.

Michael Luther, Ph.D., MBA, and CEO of STRM.BIO, expressed enthusiasm about welcoming Recordati as a lead investor, stating, “This backing, alongside that of our long-standing partners, positions us to firmly validate our transformative platform focused on hematological disorders. Our initial goal is to develop solutions for Fanconi anemia, a rare blood disorder that could pave the way for addressing further rare diseases.”

The MV platform represents a significant innovation in gene therapy, providing a non-viral, cell-based approach that could potentially resolve many issues faced by existing viral and synthetic delivery systems. This delivery method promises efficient, safe, and targeted administration of intricate genetic materials directly to bone marrow. It also allows for multiple administration opportunities as required, enhancing the efficacy of treatments.

With the financial support from Series Seed 2 funding, STRM.BIO aims to achieve significant milestones related to platform validation and expedite its clinical trial pipeline. Furthermore, the funds will also facilitate preparations for an upcoming Series A financing round.

STRM.BIO is committed to overcoming longstanding barriers in gene therapy. Their platform's efficiency in delivering genetic materials positions them uniquely in the biopharmaceutical realm and highlights their dedication to advancing safe and effective treatments for patients suffering from rare and challenging conditions. This investment not only underscores investor confidence but also reflects a growing commitment to support biotechnology innovations that could reshape future healthcare landscapes.

About STRM.BIO

STRM.BIO specializes in innovative biotechnological solutions, developing a novel, non-viral delivery system designed for the safe and effective in vivo administration of genetic therapies. With its MV platform, STRM.BIO targets the significant limitations of traditional delivery mechanisms, unlocking therapeutic potentials across various fields of genetic medicine, including gene editing and RNA therapies. The company's headquarters is located in Cambridge, Massachusetts.

For more information, visit www.strm.bio and follow STRM.BIO on LinkedIn for the latest updates.